New capabilities provide increased biologically relevant data for
improved efficiency in the drug discovery process
WALTHAM, Mass.--(BUSINESS WIRE)--
PerkinElmer,
Inc., a global leader focused on the health and safety of people and
the environment, has announced enhancements for its Operetta®
High Content Imaging System, designed to significantly improve the
ability of scientists to perform live cell assays with higher
throughput, to help foster a better understanding of normal and aberrant
cellular behavior.
The latest version of Operetta's software, Harmony 3.5, enables scientists to track individual cells over time for a better understanding of dynamic processes and to generate more accurate prediction models. (Photo: Business Wire)
Scientists conducting research in the areas of cancer, stem cells or
infectious diseases will benefit from the Operetta system's new
capabilities to analyze the dynamic behavior of cells using advanced
live cell, high content imaging. With the new capabilities, users will
be able to accurately observe individual cell behavior over time to
better understand dynamic processes in order to generate more accurate
prediction models, for example how cancer cells migrate during
metastasis or how viruses invade cells.
"We are seeing a trend towards researchers using biological assays that
are better models of the physiological environment in vivo
earlier in the drug discovery process in order to improve the likelihood
of a drug succeeding at clinical trial." said Jim Corbett, President,
Diagnostics and Life Sciences, PerkinElmer. "With these new live cell
imaging capabilities, our customers will have easy access to a wider
range of applications than ever before and will be able to generate more
biologically relevant data on how cells respond to compounds, helping to
reduce false positives later in the drug discovery process."
The Operetta system's new capabilities include brightfield imaging and
environmental chamber options, and a new transmitted light digital
phase-contrast mode that enables users to image and segment live cells
without using fluorescent dyes. This feature reduces toxic effects of
nuclear stains that may negatively impact the viability of cells,
enabling longer and more predictive live cell studies. Furthermore, it
can help to reduce assay costs.
In addition to the live cell imaging capabilities, the upgraded Operetta
system is integrated with advanced informatics solutions, such as
PerkinElmer's Columbus™
Image Data Storage and Analysis System for high content imaging data,
and the TIBCO®Spotfire®
software for data analysis and visualization which enables users to
easily combine findings across experiments.
Visit www.perkinelmer.com/Operetta
for more information
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The Company reported revenue of
approximately $2.1 billion in 2012, has about 7,500 employees serving
customers in more than 150 countries, and is a component of the S&P 500
Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
TIBCO and Spotfire are registered trademarks of TIBCO Software Inc.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130724005135/en/
Edelman (On behalf of PerkinElmer, Inc.)
Paul Barren, 404-460-9679
paul.barren@edelman.com
Source: PerkinElmer, Inc.
News Provided by Acquire Media